Skip to main content

Table 3 LS mean (95% CI) change from baseline in trough FEV1 at Day 169

From: Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis

Patient group/subgroup

UMEC/VI vs PBO

UMEC vs PBO

VI vs PBO

UMEC/VI vs UMEC

UMEC/VI vs VI

Δ mL

Δ %

Δ mL

Δ %

Δ mL

Δ %

Δ mL

Δ %

Δ mL

Δ %

ITT population (N = 3021)

200

17.8

136

11.8

96

8.5

64

5.4

104

8.6

(173, 228)

(15.4, 20.3)

(109, 164)

(9.5, 14.1)

(69, 124)

(6.2, 10.7)

(40, 88)

(3.5, 7.4)

(80, 128)

(6.7, 10.6)

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

Patient subgroups

 Maintenance-naïve

209

17.2

149

12.3

137

11.6

60

4.3

72

5.1

 (n = 984)

(159, 260)

(13.1, 21.5)

(97, 202)

(8.3, 16.6)

(85, 189)

(7.6, 15.7)

(14, 106)

(1.0, 7.7)

(27, 117)

(1.8, 8.4)

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p = 0.011

p = 0.010

p = 0.002

p = 0.002

 On maintenance

195

18.1

131

11.6

75

6.9

63

5.8

120

10.5

 (n = 2037)

(162, 227)

(15.2, 21.2)

(99, 163)

(8.8, 14.4)

(42, 107)

(4.2, 9.6)

(35, 91)

(3.5, 8.2)

(91, 148)

(8.1, 13.0)

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

 ICS-free (n = 1543)

204

17.7

150

12.9

127

11.1

54

4.2

76

5.9

(164, 243)

(14.4, 21.1)

(110, 190)

(9.7, 16.2)

(88, 167)

(8.0, 14.4)

(19, 88)

(1.6, 6.8)

(41, 111)

(3.3, 8.6)

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p = 0.003

p = 0.001

p < 0.001

p < 0.001

 ICS-treated (n = 1478)

198

18.1

124

10.8

64

5.8

74

6.6

134

11.7

(160, 236)

(14.6, 21.7)

(86, 162)

(7.5, 14.1)

(26, 102)

(2.6, 9.0)

(41, 107)

(3.9, 9.5)

(101, 168)

(8.8, 14.7)

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p = 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

 Low rescue use

206

17.2

158

13.0

101

8.3

48

3.7

105

8.2

 (n = 1488)

(169, 243)

(14.1, 20.4)

(121, 195)

(10.0, 16.1)

(64, 139)

(5.4, 11.3)

(16, 80)

(1.3, 6.1)

(72, 137)

(5.7, 10.7)

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p = 0.003

p = 0.002

p < 0.001

p < 0.001

 High rescue use

194

18.4

113

10.3

88

8.3

81

7.3

106

9.4

 (n = 1490)

(153, 235)

(14.7, 22.3)

(72, 154)

(6.8, 13.9)

(47, 129)

(4.9, 11.8)

(44, 118)

(4.3, 10.5)

(69, 142)

(6.3, 12.5)

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

p < 0.001

  1. Δ, pairwise treatment comparison; low rescue use: < 3.6 puffs/day; high rescue use: ≥ 3.6 puffs/day
  2. BL baseline, CI confidence interval, ICS inhaled corticosteroid, ITT intent-to-treat, LS least squares, PBO placebo, UMEC umeclidinium, VI vilanterol
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us